125174-24-5

Basic information

• Product Name: 3-(2-bromoethoxy)benzamide
• Synonyms: 3-(2-bromoethoxy)benzamide
• CAS NO: 125174-24-5
• Molecular Weight: 244.088
• Mol File: 125174-24-5.mol

Chemical Properties

• CAS DataBase Reference: 3-(2-bromoethoxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-bromoethoxy)benzamide(125174-24-5)
• EPA Substance Registry System: 3-(2-bromoethoxy)benzamide(125174-24-5)

Safety Data

• Hazardous Substances Data: 125174-24-5(Hazardous Substances Data)

Upstream product

• 40812-76-8 3-hydroxybenzoyl chloride 
• 618-49-5 3-hydroxybenzamide 
• 106-93-4 ethylene dibromide 
• 99-06-9 3-Carboxyphenol 

Downstream Products

• 125174-37-0 3-(2-{Methyl-[2-(4-nitro-phenyl)-ethyl]-amino}-ethoxy)-benzamide 
• 125174-54-1 3-(2-{[2-(4-Amino-phenyl)-ethyl]-methyl-amino}-ethoxy)-benzamide 
• 115256-23-0 3-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-benzamide 
• 1446753-89-4 3-(2-(benzo[d]thiazol-2-ylthio)ethoxy)benzamide 
• 712262-45-8 3-(2-aminoethoxy)benzamide 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ

Novel 3-elongated arylalkoxybenzamide derivatives were designed, synthesized and evaluated for their cell division inhibitory activity and antibacterial activity. Among them, the subseries of 3-alkyloxybenzamide derivatives exhibited greatly improved on-t